Selection of Optimum Formulation of RBD-Based Protein Sub-Unit COVID19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions